TNP-470, a potent angiogenesis inhibitor, amplifies human T lymphocyte activation through an induction of nuclear factor-κB, nuclear factor-AT, and activation protein-1 transcription factors

Laboratory Investigation

Volumn 80, Issue 1, 2000, Pages 13-21

  Locigno, Roberto ^b   Antoine, Nadine ^b   Bours, Vincent ^b   Daukandt, Marc ^b   Heinen, Ernst ^b   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR; TRANSCRIPTION FACTOR AP 1;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR; TUMOR BLOOD FLOW; TUMOR GROWTH;

EID: 0033956964     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780003     Document Type: Article

References (42)

1. Alberola-Ila J, Takaki S, Kerner JD, and Perlmutter RM (1997). Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 15:125-154.
2. Angel P and Karin M (1991). The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129-157.
3. Antoine N, Bours V, Heinen E, Simar LJ, and Castronovo V (1995). Simulation of human B-lymphocyte proliferation by AGM-1470, a potent inhibitor of angiogenesis. J Natl Cancer Inst 87:136-139.
4. Antoine N, Daukandt M, Heinen E, Simar LJ, and Castronovo V (1996a). In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor. Am J Pathol 148:393-398.
5. Antoine N, Daukandt M, Locigno R, Heinen E, Simar LJ, and Castronovo V (1996b). The potent angioinhibin AGM-1470 stimulates normal but not human tumoral lymphocytes. Tumori 82:27-30.
6. Baijum A (1968). Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest Suppl 21:77-89.
7. Bemer V, Rovira P, and Truffa-Bachi P (1995). T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Res Immunol 146:249-262.
8. Berger AE, Dortch KA, Staite ND, Mitchell MA, Evans BR, and Holm MS (1993). Modulation of T lymphocyte function by the angiogenesis inhibitor AGM-1470. Agents Actions 39 Spec No:C86-C88.
9. Brem H and Folkman J (1993). Analysis of experimental antiangiogenic therapy. J Pediatr Surg 28:445-450; discussion 450-451.
10. Bressler P, Pantaleo G, Demaria A, and Fauci AS (1991). Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes. J Immunol 147:2290-2294.
11. Castronovo V and Belotti D (1996). TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 32A:2520-2527.
12. Crabtree GR and Clipstone NA (1994). Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 63:1045-1083.
13. Flanagan WM, Corthesy B, Bram RJ, and Crabtree GR (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A (See comments). Nature 352:803-807.
14. Ginn-Pease ME and Whisler RL (1998). Redox signals and NF-kappaB activation in T cells. Free Radic Biol Med 25: 346-361.
15. Go C and Miller J (1992). Differential induction of transcription factors that regulate the interleukin 2 gene during anergy induction and restimulation. J Exp Med 175:1327-1336.
16. Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, and Liu JO (1998). Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci USA 95:15183-15188.
17. Hasuike T, Hino M, Yamane T, Nishizawa Y, Morii H, and Tatsumi N (1997). Effects of TNP-470, a potent angiogenesis inhibitor, on growth of hematopoietic progenitors (Letter). Eur J Haematol 58:293-294.
18. lngber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, and Folkman J (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557.
19. Jain J, McCaffrey PG, Valge-Archer VE, and Rao A (1992). Nuclear factor of activated T cells contains Fos and Jun. Nature 356:801-804.
20. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, lngber D, and Folkman J (1991). Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070-1076.
21. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, lngber D, and Folkman J (1994). Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212-216.
22. Lanzavecchia A (1997). Understanding the mechanisms of sustained signaling and T cell activation (comment). J Exp Med 185:1717-1719.
23. Masuda ES, Imamura R, Amasaki Y, Arai K, and Arai N (1998). Signalling into the T-cell nucleus: NFAT regulation. Cell Signal 10:599-611.
24. McNamara DA, Harmey JH, Walsh TN, Redmond HP, and Bouchier-Hayes DJ (1998). Significance of angiogenesis in cancer therapy. Br J Surg 85:1044-1055.
25. Peacock JS, Colsky AS, and Pinto VB (1990). Lectins and antibodies as tools for studying cellular interactions. J Immunol Methods 126:147-157.
26. Peseckis SM, Deichaite I, and Resh MD (1993). lodinated fatty acids as probes for myristate processing and function: Incorporation into pp60v-src. J Biol Chem 268:5107-5114.
27. Rao A (1994). NF-ATp: A transcription factor required for the co-ordinate induction of several cytokine genes, Immunol Today 15:274-281.
28. Rao A, Luo C, and Hogan PG (1997). Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 15:707-747.
29. Reynolds (1963). The'use of aronyl acetate and lead citrate in the preparation of ultrathin sections for electron microscopy. J Cell Biol 17:208-212.
30. Sakoda T, Hirata K, Kuroda R, Miki N, Suematsu M, Kawashima S, and Yokoyama M (1995). Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide. Mol Cell Biochem 152:143-148.
31. Schmidt A, Hennighausen L, and Siebenlist U (1990). Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner. J Virol 64:4037-4041.
32. Schoof DD, Obando JA, Cusack JC Jr, Goedegebuure PS, Brem H, and Eberlein TJ (1993). The influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro, Int J Cancer 55:630-635.
33. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, and Crabtree GR (1988). Identification of a putative regulator of early T cell activation genes. Science 241:202-205.
34. Siebenlist U, Franzoso G, and Brown K (1994). Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405-455.
35. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, and Crews CM (1997). The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94:6099-6103.
36. Szabo SJ, Glimcher LH, and Ho IC (1997). Genes that regulate interleukin-4 expression in T cells. Curr Opin Immunol 9:776-781.
37. Takamiya Y, Friedlander RM, Brem H, Malick A, and Martuza RL (1993). Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 78:470-476.
38. Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
39. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, and Mitchell JB (1998). The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19:711-721.
40. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, and Fujita T (1993). Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53: 5233-5236.
41. Yanase T, Tamura M, Fujita K, Kodama S, and Tanaka K (1993). Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53:2566-2570.
42. Zhao H and Koretzky GA (1997). Regulation of signal transduction through the T cell antigen receptor. J Lab Clin Med 130:126-131.